Since 1926, the Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media.

Headquartered in Paris, France, Guerbet is a publicly traded company holding more than 25% of the European market share and 7% of the worldwide contrast media market. Guerbet makes full use of its know-how and innovative capacity to meet the major public health challenges of the 21st century. The Guerbet teams contribute to progress made in the diagnosis of major disease areas (cancer, cardiovascular, inflammatory and neurodegenerative diseases). Our novel and effective imaging solutions improve patient management throughout the world.